The company is mainly engaged in the production of monoclonal antibody drugs, with a total investment of US$200 million, and plans to build a plant area of over 30,000 square meters. It aims to establish an internationally advanced antibody drug preparation system that meets GMP standards, in order to create a highland for domestic antibody drug production.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
